NEW YORK – Enliven Therapeutics, a Boulder, Colorado-based precision oncology company, emerged from stealth mode this week and announced its launch on Monday.
The company, founded in 2019, aims to advance first-in-class cancer drugs in areas of unmet need that target genomic drivers of cancer. The company said in a statement that it has raised $55 million to date in seed funding and in an insider-led Series A financing round. OrbiMed and 5AM Ventures provided seed capital and participated in the Series A raise with Roche Venture Fund.
Enliven's mission is "to help patients with cancer to not only live longer, but better," the company said in a statement. The company will aim to improve on the tolerability and efficacy of existing precision medicines. Although Enliven hasn't yet publicly detailed its drug pipeline, generally the development focus will be on therapies for solid and blood cancer indications currently being treated with suboptimal approaches.
"We recognize that for many patients on existing therapies, there are limitations that diminish gains in survival," said CEO and Co-Founder Sam Kintz. "At Enliven, we rely on our strengths — deep knowledge of effective drug development, rooted in medicinal chemistry expertise — to efficiently address challenges like resistance and poor drug tolerability that impact patients' longevity and quality of life."